SCHEMBL7674622

SCHEMBL7674622

C[C@@H](Cn1ccc2cc(F)c(I)cc21)NC(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 8/20 0.43
HTR2A P28223 7/20 0.43
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
HTR2B P41595 1/20 0.40
AAK1 Q2M2I8 2/20 0.37
TRPA1 O75762 1/20 0.36
TRPV3 Q8NET8 1/20 0.35
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.34
HPGD P15428 1/20 0.34
APOBEC3A P31941 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD17B10 Q99714 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
GABRB1 P18505 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7674627 1.00 HTR2C (0.43) HTR2CHTR2ACYP1A2CYP3A4CYP2C9
SCHEMBL8904901 0.87 HTR2C (0.56) HTR2CHTR2ACYP1A2CYP3A4CYP2C9
SCHEMBL7677108 0.86 HTR2C (0.42) HTR2CHTR2ACYP1A2CYP3A4CYP2C9
SCHEMBL7677110 0.86 HTR2C (0.42) HTR2CHTR2ACYP1A2CYP3A4CYP2C9
SCHEMBL7679840 0.79 KMO (0.46) HTR2CHTR2ATRPA1KDM4EALDH1A1
SCHEMBL7679844 0.79 KMO (0.46) HTR2CHTR2ATRPA1KDM4EALDH1A1
SCHEMBL1435785 0.77 NPY5R (0.42) HTR2CAAK1TRPA1KDM4EALDH1A1
SCHEMBL1435781 0.77 NPY5R (0.42) HTR2CAAK1TRPA1KDM4EALDH1A1
SCHEMBL24110581 0.76 HCRTR2 (0.37) HTR2CAAK1TRPA1HSP90AA1HSP90AB1
SCHEMBL30404403 0.76 HCRTR2 (0.37) HTR2CAAK1TRPA1HSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6380238-B1 FOR THERAPY OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS, AND SLEEP APNEA VERNALIS RESEARCH LIMITED (GB) 2002-04-30 US disclosed
EP-1109784-A1 INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS VERNALIS RESEARCH LIMITED (GB) 2001-06-27 EP disclosed
WO-2000012475-A1 INDOLINE DERIVATIVES AS 5-HT2B AND/OR 5-HT2C RECEPTOR LIGANDS VERNALIS RESEARCH LIMITED (GB) 2000-03-09 WO disclosed